Erasca (ERAS) is trading lower today as the market digests a recent insider transaction disclosure. A Form 4 indicates Erasca’s Chief Legal Officer exercised options for 80,000 shares at $1.70 and sold 80,000 shares in the open market on April 1, 2026 at a $16.40 weighted-average price, leaving 25,076 shares directly owned after the transactions. (stocktitan.net)

Even when executed as an exercise-and-sell, insider sales can create short-term pressure by signaling incremental supply and prompting fast-money traders to reduce risk—especially in clinical-stage biotech names where near-term valuation is sensitive to sentiment and positioning. The disclosure also arrives after the company’s recent large equity financing, which can keep investors alert to any additional share-related headlines. (investors.erasca.com)

In late January 2026, Erasca closed an upsized public offering of 25,875,000 shares priced at $10.00 per share for roughly $258.8 million in gross proceeds, intended to fund R&D and general corporate purposes. With that financing in the rearview, day-to-day trading can still be swayed by technical factors like insider transaction headlines while investors wait for major clinical updates. (investors.erasca.com)